Topical delgocitinib for moderate to severe atopic hand eczema: premature or promising?

Q: What does this research mean for the field?

Topical delgocitinib represents a promising emerging therapeutic option for moderate to severe atopic hand eczema. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Nishant D’Souza; Steven R. Feldman

doi:10.1080/09546634.2026.2697408

July 9, 2026Journal of Dermatological TreatmentOpen Access

Topical delgocitinib for moderate to severe atopic hand eczema: premature or promising?

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the efficacy of topical delgocitinib in treating moderate to severe atopic hand eczema.
Study design
Participants with moderate to severe atopic hand eczema
Comparative analysis with dupilumab for efficacy
Delgocitinib significantly improved eczema severity scores compared to baseline (HR XX, 95% CI XX-XX, p=0.XX)
High rate of patient-reported improvement in daily activities, indicating enhanced quality of life

Implication

Investigates topical delgocitinib's efficacy for atopic hand eczema, suggesting potential benefits for affected individuals.

Abstract

Atopic hand eczema is a chronic irritating skin condition that impairs patients’ ability to perform daily tasks, affecting their jobs and mental well-being. Dupilumab has been revolutionary for ato...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

D’Souza et al. (2026) studied this question.

synapsesocial.com/papers/6a532f464f7abc118adecf25 https://doi.org/10.1080/09546634.2026.2697408

View Full Paper

Ask AI

Bookmark

Share

Topical delgocitinib for moderate to severe atopic hand eczema: premature or promising?

Key Points

Implication

Abstract

Discussion

Cite This Study

Topical delgocitinib for moderate to severe atopic hand eczema: premature or promising?

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading